# Neonatal Respiratory Morbidity among Late Preterm Births by Planned Mode of Delivery and Gestational Age

- 3
- 4 Mark A. CLAPP, MD MPH<sup>1</sup>, Siguo LI, MS<sup>1</sup>, Jessica L. COHEN, PhD<sup>2</sup>, Cynthia GYAMFI-
- 5 BANNERMAN, MD, MS<sup>3</sup>, Amy B. KNUDSEN, PhD<sup>4</sup>, Scott A LORCH, MD, MSCE<sup>5</sup>,
- 6 Tanayott THAWEETHAI, PhD<sup>6</sup>, Jason D. WRIGHT, MD<sup>7</sup>, Anjali J. KAIMAL, MD MAS<sup>8</sup>\*,
- 7 Alexander MELAMED, MD MPH<sup>1</sup>\*
- 8
- <sup>1</sup> Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General
   Hospital
- <sup>2</sup> Department of Global Health and Population, Harvard T.H. Chan School of Public Health
- <sup>3</sup> Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at
   San Diego
- <sup>4</sup> Institute of Technology Assessment, Department of Radiology, Massachusetts General Hospital
- <sup>5</sup> Division of Neonatology, Children's Hospital of Philadelphia
- <sup>6</sup> Division of Biostatistics, Massachusetts General Hospital
- <sup>7</sup> Department of Obstetrics and Gynecology, Columbia University
- 18 <sup>8</sup> Department of Obstetrics and Gynecology, University of South Florida
- 20 \* Drs. Kaimal and Melamed contributed equally.
- 21

19

- 22 Corresponding Author:
- 23 Mark A Clapp, MD MPH
- 24 Department of Obstetrics, Gynecology, and Reproductive Biology
- 25 Massachusetts General Hospital
- 26 55 Fruit St, Boston, MA 02114
- 27 Email: <u>mark.clapp@mgh.harvard.edu</u>
- 28
- 29 Word Count:
- 30 Main 2,659
- 31 Abstract 381
- 32
- <u>Disclosures</u>: Dr. Clapp serves as a medical advisory board member with private equity in Delfina
   Health, outside the submitted work. Dr. Melamed reports grants from the National Center for
- 35 Advancing Translational Sciences, the National Cancer Institute, the Conquer Cancer-The
- ASCO Foundation, and the Department of Defense outside the submitted work. Dr. Melamed
- has also served as an advisor for AstraZeneca. Dr. Wright has received research funding from
- 38 Merck and honoraria from UpToDate. Dr. Gyamfi-Bannerman reports grants from NHLBI,
- 39 NICHD, and NIHMD and has received research funding from HealthCore Inc/SERA
- 40 Prognostics, Inc. and MIRVIE, Inc.
- 41 <u>Conflicts of interest</u>: The authors declare no conflicts of interest or financial support.
- 42 <u>Funding</u>: None.
- 43 Data Access, Responsibility, and Analysis: Dr. Clapp had full access to all the data in the study
- 44 and takes responsibility for the integrity of the data and the accuracy of the data analysis.
- 45 <u>Data Sharing</u>: Data used in this study is publicly available at https://dash.nichd.nih.gov/.
- 46 <u>Acknowledgments</u>: The authors have no other acknowledgments.

## 47 Precis

The absolute risk of neonatal respiratory morbidity among patients at risk for late pretermdelivery varies considerably by gestational age and mode of delivery.

50

### 51 Abstract

52 <u>Objective</u>: To estimate the effect of late preterm antenatal steroids on the absolute risk of
53 respiratory morbidity among subgroups of patients based on the planned mode of delivery and
54 gestational age at presentation.

55 <u>Methods</u>: This was a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial, a

56 multicenter trial originally conducted within the NICHD's MFMU network of individuals with

57 singleton gestations and without pre-existing diabetes who were at high risk for late preterm

58 delivery (34-36 weeks of gestation). We fit binomial regression models to estimate the absolute

risk of respiratory morbidity, with and without steroid administration, by gestational age and

60 planned mode of delivery at the time of presentation. We assumed a homogenous effect of

61 steroids on the log-odds scale, as was reported in the ALPS trial. The primary outcome was

62 neonatal respiratory morbidity, as defined in the ALPS Trial

63 <u>Results</u>: The analysis included 2,825 patients at risk for late preterm birth. The risk of respiratory

64 morbidity varied significantly by planned mode of delivery (adjusted risk ratio (aRR) 1.90 (95%)

65 confidence interval (CI) 1.55, 2.33) for cesarean compared to vaginal delivery) and day of

66 gestation at presentation (aRR 0.92 (95% CI 0.90, 0.94)). For those planning a cesarean delivery

67 and presenting in the 34th week of gestation, the risk of neonatal respiratory morbidity was

68 39.4% (95% CI 30.8, 47.9%) without steroids and 32.0% (95% CI 24.6, 39.4%) with steroids. In

69 contrast, for patients presenting in the 36th week and planning a vaginal delivery, the risk of

- reonatal respiratory morbidity was 6.9% (95% CI 5.6, 8.6%) without steroids and 5.6% (95%
- 71 4.2, 7.0%) with steroids.
- 72 <u>Conclusion</u>: The absolute risk of neonatal respiratory morbidity among patients at risk for late
- 73 preterm delivery varies considerably by gestational age at presentation and planned mode of
- 74 delivery. As only communicating the relative risk reduction of antenatal steroids for respiratory
- 75 morbidity may lead to an inaccurate perception of benefit, individualized estimates of absolute
- risk expected with and without treatment may inform shared decision-making.

# 77 Introduction

78	Neonatal respiratory morbidity, including respiratory distress syndrome and transient
79	tachypnea of the newborn, is a common complication of prematurity. <sup>1–3</sup> Multiple patient factors,
80	including gestational, mode of delivery, and fetal sex, influence the risk of respiratory
81	morbidity. <sup>2–7</sup> There is a broad and longstanding consensus that antenatal steroids decrease the
82	risk of neonatal respiratory morbidity for neonates born before 34 weeks of gestation. <sup>8,9</sup> More
83	recently, the Antenatal Late Preterm Steroid (ALPS) Trial demonstrated that this benefit extends
84	to fetuses at risk of delivery in the late preterm period (34-36 weeks of gestation): neonates
85	exposed antenatally to betamethasone in the late preterm period had a 20% risk reduction of the
86	composite respiratory outcome, without statistically conclusive evidence of treatment
87	heterogeneity among pre-specified subgroups. <sup>10</sup>
88	The Society for Maternal-Fetal Medicine recommends that clinicians and patients engage
89	in shared decision-making around steroid administration in the late preterm period. <sup>11</sup> However,
90	the baseline risk of respiratory morbidity differs substantially across the late preterm period,
91	making summary measures of absolute risk, as reported in the original trial, less informative for
92	individualized counseling. <sup>2</sup> Furthermore, communicating only the relative risk may lead to an
93	
	inaccurate perception of the benefit of antenatal steroids, especially for those with a small
94	inaccurate perception of the benefit of antenatal steroids, especially for those with a small absolute risk. <sup>12</sup> Thus, our objective in this secondary analysis of data from the ALPS Trial was
94 95	inaccurate perception of the benefit of antenatal steroids, especially for those with a small absolute risk. <sup>12</sup> Thus, our objective in this secondary analysis of data from the ALPS Trial was to estimate the absolute risk of respiratory morbidity with and without steroid administration,
94 95 96	inaccurate perception of the benefit of antenatal steroids, especially for those with a small absolute risk. <sup>12</sup> Thus, our objective in this secondary analysis of data from the ALPS Trial was to estimate the absolute risk of respiratory morbidity with and without steroid administration, based on patients' planned mode of delivery and gestational age at presentation. <sup>10</sup>

#### 98 Methods

This is a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial 99 conducted within 17 university-based hospitals within the Maternal-Fetal Medicine Units 100 101 (MFMU).<sup>10</sup> In the trial, patients with a singleton pregnancy between 34 weeks 0 days and 36 102 weeks 5 days of gestation and with a high chance of delivery in the late preterm period were 103 enrolled and randomized to receive an antenatal course of betamethasone or placebo. The 104 primary outcome was a composite of respiratory morbidity within 72 hours after delivery and 105 included the following: high-flow nasal cannula or continuous positive airway pressure (CPAP) 106 for at least 2 hours; supplemental oxygen use for at least 4 hours; extracorporeal membrane 107 oxygenation (ECMO); and/or mechanical ventilation. We also examined the secondary outcome 108 of severe respiratory complications, as defined in the ALPS Trial as "a composite outcome of 109 CPAP or high-flow nasal cannula for at least 12 continuous hours, supplemental oxygen with a 110 fraction of inspired oxygen of at least 0.30 for at least at least 24 continuous hours, ECMO or mechanical ventilation, stillbirth, or neonatal death within 72 hours after delivery."<sup>10</sup> The ALPS 111 112 trial randomized 2,831 patients to betamethasone (n=1,429) or placebo (n=1,402).<sup>10</sup> This analysis 113 included patients randomized at or after 34 weeks of gestation who were not lost to follow-up. 114 We examined the risk of neonatal respiratory morbidity among two patient factors 115 strongly associated with the risk of respiratory morbidity: mode of delivery and gestational age.<sup>2,3,5</sup> To generate results that could guide clinical decision-making and inform counseling, we 116 117 considered *planned* mode of delivery (not actual mode) and gestational age at presentation (not 118 delivery), information available to clinicians and patients when deciding about antenatal steroid administration. We defined the planned mode of delivery as "cesarean" if 1) a cesarean delivery 119 120 was scheduled in the late preterm period at the time of presentation or 2) if no delivery was

scheduled at the time of presentation but a cesarean section was performed at any gestational age for the following indications: placenta accreta, placenta previa, fetal anomaly, prior uterine surgery, or prior cesarean delivery. This definition was chosen to capture patients who were unlikely to attempt a trial of labor. The prevalence of these factors was compared between the two groups to examine for potential group imbalances in the original trial.

126 We constructed a binomial regression model that included the treatment assignment (placebo or betamethasone), planned mode of delivery, and gestational age in days and used a 127 128 log link to report risk ratios. Because the prespecified subgroup analysis in the original trial did 129 not detect signs of treatment effect heterogeneity, the model assumed a constant effect size (on 130 the log-odds scale) of the intervention across all groups. We used this regression model to 131 estimate the absolute risks of respiratory morbidity in both the treated and untreated groups. The 132 predicted (or estimated) absolute risks of this model were presented graphically by planned mode of delivery and across days of gestation; for comparison, we also plotted the observed absolute 133 risks of the outcome with a corresponding 95% confidence interval by planned mode of delivery 134 135 and weeks of gestation. To examine the model's discrimination and calibration, we used k-fold 136 cross-validation (k=10) to calculate the area under the receiver operating characteristic (ROC) 137 curves (AUC) and generate a calibration plot for both outcomes.

Additional steps were performed to further facilitate counseling around the absolute risk of respiratory morbidity and expected outcome by mode of delivery and gestational age. First, the risks of the primary and secondary outcomes were estimated using the same logistic regression model, though gestational age in weeks was used instead of gestational age in days; this allowed for the output to be summarized in a compact, interpretable table. Second, we built an online reference tool to display the estimated risk of the primary and secondary outcome

144	using a patient's precise gestational age in days at presentation and their planned mode of
145	delivery, which is available at <u>https://mghinferencelab.shinyapps.io/alps_web_calc/</u> .
146	Data was obtained with permission from the NICHD Data and Specimen Hub (DASH). <sup>13</sup>
147	The XXX Institution Review Board exempted this study. All analyses used Stata (Stata Corp,
148	College Station, TX). P-values <0.05 were considered statistically significant. The STROBE
149	reporting guidelines were followed.
150	
151	Results
152	Of the original 2,831 participants, we excluded 2 patients randomized before 34 weeks of
153	gestation and 4 patients lost to follow-up (2.1%). eTable 1 in the Supplement shows the sample
154	sizes of the various strata used in the analysis. As expected, there were no differences in
155	distributions of the planned mode of delivery or gestational age at randomization between the
156	two groups (eTable 2 in the Supplement).
157	Figure 1 shows the predicted absolute risks of respiratory morbidity among patients
158	treated with steroids and those who did not by the day of gestation and the planned mode of
159	delivery at the time of presentation. The observed rates (not those predicted by the model) by
160	week of gestation are shown on the same graph for comparison and included in eTable 3 in the
161	Supplement. The risk of respiratory morbidity varied significantly across planned modes of
162	delivery (adjusted risk ratio (aRR) 1.90 (95% confidence interval (CI) 1.55, 2.33) for cesarean
163	compared to vaginal delivery) and day of gestation at presentation (aRR 0.92 (95% CI 0.90,
164	0.94)). The unadjusted and adjusted model outputs are shown in eTable 4 in the Supplement. The
165	10-fold cross-validated AUC was 0.669 (95% CI 0.639, 0.698). The ROC curve and calibration
166	plot is shown in eFigure 1 and eFigure 2 in the Supplement.

167	The predicted absolute risks with and without treatment are summarized by week of
168	gestation in Table 1. At baseline (i.e., among those treated with the placebo), neonates born to
169	individuals planning a cesarean delivery have a 36.7% (95% CI 29.8, 43.7%) risk of respiratory
170	morbidity when presenting in the 34 <sup>th</sup> week of gestation; this risk decreases to 31.4% (95% CI
171	24.5, 37.9%) with antenatal steroids. By contrast, neonates who are born via a planned vaginal
172	delivery after presenting in the 36 <sup>th</sup> week of gestation have a 6.8% (95% CI 5.1, 8.5%) risk of
173	respiratory morbidity without steroids and a 5.4% (95% CI 4.0, 6.9%) risk with steroid
174	treatment.
175	Figure 2 shows the predicted absolute risks of severe respiratory complications among
176	those who received and did not receive antenatal steroids by day of gestational age and planned
177	mode of delivery. The observed risks are shown on the same graphs by week of gestation and are
178	included in eTable 5 in the Supplement. Planned mode of delivery (aRR 2.16 (95% CI 1.72,
179	2.72) for cesarean vs. vaginal delivery) and gestational age (aRR 0.92 (95% CI 0.90, 0.94)) were
180	significantly associated with the risk of severe respiratory complications. The unadjusted and
181	adjusted model outputs are shown in eTable 6 in the Supplement. The 10-fold cross-validated
182	AUC was 0.679 (95% CI 0.651, 0.717); the ROC curve and calibration plots are shown in
183	eFigure 3 and eFigure 4 in the Supplement. These findings are summarized by week of gestation
184	in Table 2 which tabulates the absolute risk of severe respiratory complication, with and without
185	treatment, by planned mode of delivery and week of gestational age at presentation.
186	The results of these two models are available as an interactive calculator available at
187	https://mghinferencelab.shinyapps.io/alps_web_calc/. This tool displays the estimated absolute
188	risk of respiratory morbidity (and associated 95% CIs) with and without treatment as a function

189 of day of gestation at presentation and planned mode of delivery (example shown in Figure 3).

## 190 Discussion

In this secondary analysis of the ALPS Trial, we demonstrated that the absolute risks of 191 192 neonatal respiratory morbidity vary significantly by gestational age and planned mode of 193 delivery. Notably, infants born via a planned cesarean delivery are at a much higher risk of 194 respiratory morbidity than those having a vaginal delivery, especially at earlier gestational ages 195 (approximately 37% for planned cesarean delivery at 34 weeks vs. 7% for planned vaginal 196 delivery at 36 weeks). While these relationships were previously known, we quantified this risk 197 in the late preterm period using prospectively collected data as part of the ALPS Trial. Similarly, 198 we demonstrated the challenge of predicting these outcomes for patients at the time of 199 counseling and decision-making for antenatal steroids, even in the context of a clinical trial that used a strict definition of "high risk for preterm delivery," as demonstrated by the ROC curves; 200 201 to convey the level of uncertainty around the estimates, all data are presented with 95% 202 confidence intervals. This information can inform shared decision-making about late preterm 203 steroids and allow clinicians to estimate the baseline risk of neonatal respiratory morbidity more 204 accurately. This absolute baseline risk of respiratory in the unexposed group can then be used to 205 interpret the expected relative risk reduction that was demonstrated uniformly across all enrollees 206 in the trial.

These findings must be interpreted in the context of the original ALPS Trial protocol and the trial enrollees. The ALPS Trial only enrolled patients who were at high risk of a late preterm delivery as determined by predefined clinical factors (rupture of membranes, preterm labor at  $\geq$ 3 cm dilation or  $\geq$ 75% effacement, or expected preterm delivery via induction or cesarean within 24 hours and 7 days) or provider judgment who had not previously received antenatal corticosteroids or had pregestational diabetes.<sup>10</sup> As a result, nearly 40% of enrollees delivered

213 before receiving the second dose, and the median time from presentation to delivery was approximately 30 hours.<sup>10</sup> The absolute risks reported from this trial are most relevant to patients 214 215 presenting with a similar risk of preterm delivery. For example, the benefit of antenatal steroids 216 may be higher than reported in the trial for patients who are more likely to deliver after receiving 217 a full course; in contrast, the benefit may be less if more patients received antenatal steroids but 218 went on to delivery at later gestations or full term (i.e., a lower risk of preterm delivery than the trial). Studies of late preterm antenatal steroids outside of the context of a clinical trial are 219 220 needed to better estimate the absolute risks of respiratory morbidity and the benefit of the 221 intervention.

222 The original trial did include subgroup comparisons for several factors, including planned 223 cesarean delivery and gestational age, though gestational age was analyzed as 34-35 vs. 36 224 weeks of gestation. The study reported no significant effects for the interaction terms for the 225 primary outcome when each factor was analyzed individually; however, the trial was not 226 powered to detect differences in the primary outcome within subgroups. The possibility of a 227 differential impact of betamethasone in actual practice (i.e., treatment effect heterogeneity) 228 remains plausible, especially considering the differences in the number of days between first 229 dose and delivery and the number of patients who received a full course of betamethasone before 230 delivery by planned mode of delivery and gestational age at presentation. Investigations of 231 treatment effect heterogeneity should be a focus of future research to further individualize 232 counseling on risks and benefits.

This study focused on counseling regarding the individualized benefits of antenatal steroids among two common and known clinical factors across which the baseline risk of respiratory morbidity varies widely. However, other factors may inform clinical decision-

236 making, especially the known and theoretical intervention risks. Hypoglycemia, which was more 237 likely in the treatment group in the ALPS Trial (RR 1.60 (95% CI 1.37-1.87)), also likely varies among population subgroups (e.g., gestational age).<sup>10,14,15</sup> We could not investigate the absolute 238 239 risks of hypoglycemia across gestational age and mode of delivery because these data are not publicly available due to ongoing data collection at the time of this analysis.<sup>13</sup> Furthermore, there 240 241 is no data available to inform individualized counseling on the associations between long-term 242 neurocognitive or developmental risks and antenatal steroids in the late preterm period. Available 243 evidence in other populations is mixed, though a single dose of antenatal steroids in the early preterm period has not been shown to increase long-term neurodevelopment risks.<sup>16–21</sup> 244 245 The study is strengthened by its use of rigorously collected data as part of a large 246 randomized controlled trial, allowing us to estimate the rates of respiratory morbidity among 247 those exposed and unexposed to antenatal steroids in the late preterm period. However, it is 248 limited in that the trial enrollees may not reflect the general population at risk for late preterm 249 birth or considering antenatal steroids. As mentioned, the baseline risks of respiratory morbidity 250 are presented for individuals with a high likelihood of delivery in the late preterm period.<sup>10</sup> The 251 baseline risks may vary in a population without the same likelihood of preterm delivery. 252 Similarly, the original trial was not powered to detect differences within population subgroups. 253 As such, the number of patients within our strata varies, some of which are small, leading to 254 considerable uncertainty. To help quantify this uncertainty, 95% confidence intervals are 255 provided in Tables 1 and 2 and in the online calculator. Other factors may also contribute to a 256 neonate's risk for respiratory morbidity. However, this study focused on two patient-specific 257 factors that would be known at the time of presentation and have previously been shown to have 258 a significant effect on risk in the literature; future studies could try to improve the performance

259 of the predictive model for respiratory morbidity using other factors, though the baseline 260 challenge of predicting who and when a patient will deliver in the preterm period likely will 261 continue to limit model discrimination. Last, we acknowledge that many non-patient factors may 262 affect clinical decision-making surrounding ALPS (e.g., hospital resources, etc.); this information 263 and the visualization tool are intended to help conceptualize the absolute risk reduction of 264 respiratory morbidity with ALPS, which may inform one aspect of the shared decision-making. 265 In conclusion, the absolute risk of neonatal respiratory morbidity among patients at high 266 risk for late preterm delivery varies considerably by gestational age at presentation and planned 267 mode of delivery. Assuming no treatment effect heterogeneity (i.e., a constant relative risk 268 reduction among all subgroups), patients with a low baseline risk (e.g., those presenting in the 36<sup>th</sup> week and planning a vaginal delivery) can expect to obtain a considerably smaller absolute 269 270 benefit from steroid administration compared to patients at the highest risk of neonatal respiratory morbidity (e.g., those presenting in the 34<sup>th</sup> week and planning a cesarean delivery).; 271 272 Accurate understanding of these anticipated benefits and potential risks is critical to patients' 273 making decisions based on informed patient preferences. Studies adequately powered to compare 274 the risks and benefits of antenatal late preterm steroids among population subgroups, and their 275 effectiveness outside the context of a clinical trial, are needed to increase the precision of shared 276 decision-making and public policy surrounding late preterm steroids.

## 277 References

- Mahoney AD, Jain L. Respiratory disorders in moderately preterm, late preterm, and early term infants. *Clin Perinatol*. 2013;40(4):665-678. doi:10.1016/j.clp.2013.07.004
- Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births. *JAMA*. 2010;304(4):419-425. doi:10.1001/jama.2010.1015
- 3. De Luca R, Boulvain M, Irion O, Berner M, Pfister RE. Incidence of early neonatal mortality
  and morbidity after late-preterm and term cesarean delivery. *Pediatrics*. 2009;123(6):e10641071. doi:10.1542/peds.2008-2407
- 4. Mekic N, Selimovic A, Cosickic A, et al. Predictors of adverse short-term outcomes in late
  preterm infants. *BMC Pediatr*. 2023;23(1):298. doi:10.1186/s12887-023-04112-z
- Berthelot-Ricou A, Lacroze V, Courbiere B, Guidicelli B, Gamerre M, Simeoni U.
   Respiratory distress syndrome after elective caesarean section in near term infants: a 5-year cohort study. *J Matern Fetal Neonatal Med.* 2013;26(2):176-182.
   doi:10.3109/14767058.2012.733743
- Altman M, Vanpée M, Cnattingius S, Norman M. Risk factors for acute respiratory morbidity
  in moderately preterm infants. *Paediatr Perinat Epidemiol*. 2013;27(2):172-181.
  doi:10.1111/ppe.12035
- 294 7. Condò V, Cipriani S, Colnaghi M, et al. Neonatal respiratory distress syndrome: are risk
  295 factors the same in preterm and term infants? *J Matern Fetal Neonatal Med.*296 2017;30(11):1267-1272. doi:10.1080/14767058.2016.1210597
- Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for
   women at risk of preterm birth. *Cochrane Database Syst Rev.* 2006;(3):CD004454.
   doi:10.1002/14651858.CD004454.pub2
- Gilstrap LC, Christensen R, Clewell WH, et al. Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes: NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. *JAMA*. 1995;273(5):413-418.
   doi:10.1001/jama.1995.03520290065031
- 304 10. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women
   305 at Risk for Late Preterm Delivery. *New England Journal of Medicine*. 2016;374(14):1311 306 1320. doi:10.1056/NEJMoa1516783
- Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal
   Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late
   preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal
   corticosteroids in the late preterm birth period in women at risk for preterm delivery, August
- 311 2016. *American Journal of Obstetrics & Gynecology*. 2021;225(5):B36-B42.
- doi:10.1016/j.ajog.2021.07.023

- 313 12. Freeman ALJ. How to communicate evidence to patients. *Drug Ther Bull*. 2019;57(8):119 314 124. doi:10.1136/dtb.2019.000008
- 315 13. NICHD DASH Eunice Kennedy Shriver National Institute of Child Health and Human
   316 Development Data and Specimen Hub. Accessed November 11, 2023.
   317 https://dash.nichd.nih.gov/
- 318 14. Bromiker R, Perry A, Kasirer Y, Einav S, Klinger G, Levy-Khademi F. Early neonatal
  319 hypoglycemia: incidence of and risk factors. A cohort study using universal point of care
  320 screening. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2019;32(5):786-792.
  321 doi:10.1080/14767058.2017.1391781
- 15. Lubchenco LO, Bard H. INCIDENCE OF HYPOGLYCEMIA IN NEWBORN INFANTS
  CLASSIFIED BY BIRTH WEIGHT AND GESTATIONAL AGE. *Pediatrics*.
  1971;47(5):831-838. doi:10.1542/peds.47.5.831
- 16. Räikkönen K, Gissler M, Tapiainen T, Kajantie E. Associations Between Maternal Antenatal
  Corticosteroid Treatment and Psychological Developmental and Neurosensory Disorders in
  Children. *JAMA Network Open*. 2022;5(8):e2228518.
  doi:10.1001/jamanetworkopen.2022.28518
- 17. Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Evaluation of Long-term
  Outcomes Associated With Preterm Exposure to Antenatal Corticosteroids: A Systematic
  Review and Meta-analysis. *JAMA Pediatrics*. 2022;176(6):e220483.
  doi:10.1001/jamapediatrics.2022.0483
- 18. van der Merwe JL, Sacco A, Toelen J, Deprest J. Long-term neuropathological and/or
  neurobehavioral effects of antenatal corticosteroid therapy in animal models: a systematic
  review. *Pediatr Res.* 2020;87(7):1157-1170. doi:10.1038/s41390-019-0712-1
- 19. Thevathasan I, Said JM. Controversies in antenatal corticosteroid treatment. *Prenatal Diagnosis*. 2020;40(9):1138-1149. doi:10.1002/pd.5664
- 20. Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological
  functioning and health related quality of life 31 years after inclusion in randomised
  controlled trial. *BMJ*. 2005;331(7518):665. doi:10.1136/bmj.38576.494363.E0
- 341 21. Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G.
  342 Neurodevelopmental Outcome After a Single Course of Antenatal Steroids in Children Born
  343 Preterm: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2015;125(6):1385-1396.
  344 doi:10.1097/AOG.0000000000748

345

346

347 Figure 1: Risk of respiratory morbidity among individuals exposed and not exposed to antenatal

348 steroids by gestational age and planned mode of delivery

349



350 351

The lines represent the estimated rates of respiratory morbidity among those exposed (+ ALPS) and not exposed (- ALPS) that were derived from a logistic regression model that included

354 gestation age at presentation (in days), planned mode of delivery (vaginal vs. cesarean), and

treatment group. For comparison, the observed rates (i.e., "actual risk") with their corresponding

356 95% confidence interval (CI) by week (not day) of gestation are also plotted; of note, their

357 position on the x-axis does not correspond to a specific day within the week of gestation.

358

Figure 2: Risk of severe respiratory complications among individuals exposed and not exposed

to antenatal steroids by gestational age and planned mode of delivery

361



362 363

The lines represent the estimated rates of severe respiratory complications among those exposed (+ ALPS) and not exposed (- ALPS) that were derived from a logistic regression model that included gestation age at presentation (in days), planned mode of delivery (vaginal vs. cesarean), and treatment group. For comparison, the observed rates (i.e., "actual risk") with their corresponding 95% confidence interval (CI) by week (not day) of gestation are also plotted; of note, their position on the x-axis does not correspond to a specific day within the week of gestation.

- 372 Figure 3: Image of online calculator to estimate the absolute risks of respiratory morbidity by
- 373 planned mode of delivery and gestational age with and without antenatal steroids
- 374

#### Absolute Risk of Respiratory Morbidity for Neonates at High Risk for Late Preterm Birth

The following model estimates the absolute risk of respiratory outcomes for singleton gestations at high risk for late preterm birth using data from the ALPS Trial. In the trial, *high risk for preterm delivery* was defined by the following criteria: rupture of membranes, preterm labor at  $\geq$ 3 cm dilation or  $\geq$ 75% effacement, expected preterm delivery via induction or cesarean within 24 hours and 7 days, or provider judgment. Risk estimates are a function of the planned mode of delivery and gestational age (in days) at the time of presentation and are presented between the trial's control group ('Without Steroids') and intervention group ('With Steroids').

Please note: This tool is only for research purposes, and the findings have not been externally validated. Confidence intervals around the point estimates are shown to reflect the degree of uncertainty.



#### **Outcome Definitions**

#### Respiratory Morbidity

Respiratory support <72 hours after birth is defined as any of the following: the use of CPAP or high-flow nasal cannula for  $\geq$ 2 consecutive hours, supplemental oxygen with a FiO2  $\geq$ 0.30 for  $\geq$ 4 continuous hours, ECMO, or mechanical ventilation.

#### Severe Respiratory Complication

Defined as any of the following: CPAP or high-flow nasal cannula for  $\ge 2$  continuous hours, supplemental oxygen with FiO2  $\ge 0.30$  for  $\ge 24$  continuous hours, ECMO or mechanical ventilation, stillbirth, or neonatal death within 72 hours after delivery.

## 376

Table 1: Estimated risk of respiratory morbidity among neonates not exposed and exposed to

antenatal steroids, stratified by week of gestation and planned mode of delivery

379

Week of	Planned Vaginal Delivery		Planned Cesarean Delivery	
Gestation at	No ALPS	ALPS	No ALPS	ALPS
Presentation	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
34 weeks	20.9 (17.5-24.4)	17.0 (13.9-20.2)	39.4 (30.8, 47.9)	32.0 (24.6-39.4)
35 weeks	11.8 (9.6-14.1)	9.6 (7.7-11.5)	22.3 (17.3-27.3)	18.1 (14.0-22.3)
36 weeks	6.9 (5.2-8.6)	5.6 (4.2-7.0)	12.9 (9.3-16.6)	10.6 (7.5-13.)

380

381 ALPS, antenatal late preterm steroids; CI, confidence interval.

382

383

- Table 2: Estimated risk of severe respiratory complications among neonates not exposed and
- exposed to antenatal steroids, stratified by week of gestation and planned mode of delivery

386

Week of	Planned Vaginal Delivery		Planned Cesarean Delivery	
Gestation at	No ALPS	ALPS	No ALPS	ALPS
Presentation	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
34 weeks	17.3 (14.1-20.1)	11.6 (9.0-14.2)	37.0 (28.1-45.9)	24.8 (18.1-31.4)
35 weeks	9.4 (7.6-11.8)	6.5 (5.0-8.1)	20.8 (15.6-25.9)	13.9 (10.2-17.6)
36 weeks	5.0 (3.5-6.4)	3.3 (2.3-4.4)	10.6 (7.1-14.1)	7.1 (4.7-9.5)

387

388 ALPS, antenatal late preterm steroids; CI, confidence interval.